GILD Gilead Sciences, Inc

0  0%
Previous Close 0.00
Open 0.00
Price To book 0.00
Market Cap
Shares 0
Volume 0
Short Ratio 0.00
Av. Daily Volume 0

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 ongoing.
Ulcerative Colitis
Phase 3 ongoing.
Crohn's Disease
Phase 3 ongoing.
Rheumatoid Arthritis
Phase 3 futility analysis 3Q 2017.
Gastric Cancer
Phase 3 trial initiated.
Pre exposure prophylaxis
Phase 3 data due mid-2017 with possible NDA filing 3Q 2017.
Phase 3 planned.
Selonsertib (GS-4997)
Alcoholic Hepatitis
Phase 3 planned.
Selonsertib (GS-4997)
Nonalcoholic steatohepatitis (NASH)
Phase 2 data due 4Q 2017.
Nonalcoholic steatohepatitis (NASH)
Phase 2 data due 3Q 2017.
Nonalcoholic steatohepatitis (NASH)
Phase 3 planned.
Acute Myeloid Leukemia
Announced NDA filing December 8, 2016.
Hepatitis C virus (HCV)

Latest News

  1. Biotech Stock Roundup: Biogen Gains on Strong Q1, NASH Data on Gilead Drug
  2. Gilead (GILD) Q1 Earnings: Stock Likely to Beat Estimates?
  3. Gilead Sciences: NASH Bridges…To What?
  4. 3 Stocks Could Double Their Dividends -- But Shouldn't
  5. America's 12 Most Charitable Companies
  6. Better Buy: Gilead Sciences vs. Celgene
  7. Gilead Sciences: Know Hope…or No Hope?
  8. Is Pain Ahead for Healthcare ETFs After Weak JNJ Q1?
  9. 11 Most Profitable Companies In The Fortune 500
  10. Should Gilead Sciences Be Worried About Allergan?
  11. Why Now Is Not the Time to Buy Valeant Pharmaceuticals
  12. Gilead Sciences: Just Like Thermopylae?
  13. Should Gilead Sciences Acquire NewLink Genetics?
  14. Gilead Announces Scientific Presentations Demonstrating Efficacy of Harvoni® (Ledipasvir/Sofosbuvir) in Special Patient Populations With HCV Infection
  15. 10 Reasons Merck Could Be the World's Most Perfect Stock
  16. 3 Reasons Gilead Sciences Is a Better Dividend Stock Than Johnson & Johnson
  17. Gilead Presents Proof-of-Concept Data for GS-0976 in Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress™ 2017
  18. Gilead Presents Data at the International Liver Congress™ 2017 Supporting the Efficacy and Safety of Vemlidy in Patients with Chronic Hepatitis B After 96 Weeks, and Also After Switching From Viread
  19. Gilead to Present Clinical and Preclinical Data on Nonalcoholic Steatohepatitis (NASH) at The International Liver Congress™ 2017
  20. Gilead Sciences: Who's Frustrated Now?